Related Experiment Videos
Evaluation of cell surface antigens as potential targets for recombinant tumor toxins
1Institute for Experimental Cancer Research, Tumor Biology Center, Freiburg, Germany.
Abstract:
Tumor toxins are recombinant polypeptides derived from the fusion of a single-chain antibody domain or a ligand specific for a cell surface receptor with the enzymatic domain of a bacterial or plant toxin. If these receptors are preferentially expressed on the surface of tumor cells, the tumor toxins can serve as efficient therapeutics. Examples in which growth factors, cytokines, hormones or antibody domains have been fused to toxins have been described and the bacterially expressed molecules have shown anti-tumor effects in vitro and in vivo. Since many tumors are not sensitive to the existing tumor toxins, the search continues for new antigens with tumor specific or tumor enhanced expression. We explored three antigenic structures for their possible use as targets for tumor toxins, i.e. (a) a glycosphingolipid with an Le(a) antigenic structure which is overexpressed in gastrointestinal carcinomas, e.g. colon carcinoma, (b) the epithelial glycoprotein episialin which shows altered expression in various tumor tissues such as breast, ovary and pancreas and (c) the neurotensin receptor which is found on NSLC, pancreatic and colonic cancer cells. For targeting the tumor toxin to the carbohydrate structures, we constructed recombinant single-chain antibody domains (scFv) fused to a truncated form of the exotoxin A from Pseudomonas aeruginosa (ETA). In the case of the neurotensin receptor, the ligand neurotensin was exploited to construct a recombinant fusion protein with exotoxin A as the effector domain. Binding experiments showed that the recombinant proteins are able to specifically recognize their respective target structures. In vitro cytotoxicity assays with neurotensin-ETA showed specific killing activity for receptor positive tumor cell lines. For the scFv-ETA constructs we could not observe in vitro tumor toxicity. We conclude that the antigenic targets for tumor toxins have to be carefully chosen and that specific cell binding activity is not a sufficient criterion for tumor cell killing. The neurotensin-ETA, a new anti-tumor agent, shows that seven transmembrane spanning receptors are potential targets which allow toxin binding and promote cell killing through the appropriate internalization.
Insights
Researchers explored new tumor toxin targets, fusing antibodies or ligands to toxins. While neurotensin receptor targeting showed anti-tumor effects, antibody-toxin fusions did not, highlighting careful target selection for effective cancer therapeutics.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- Tumor toxins are engineered therapeutics combining cell-targeting moieties with cytotoxic payloads.
- Existing tumor toxins have limitations, necessitating the identification of novel tumor-specific antigens.
- Recombinant fusion proteins offer a promising strategy for targeted cancer therapy.
Purpose of the Study:
- To evaluate novel antigenic targets for tumor toxin development.
- To construct and assess the efficacy of single-chain antibody-exotoxin A (scFv-ETA) and neurotensin-exotoxin A (NT-ETA) fusion proteins.
- To determine the correlation between target binding and in vitro tumor cell killing.
Main Methods:
- Construction of scFv-ETA fusion proteins targeting Le(a) glycosphingolipid and episialin.
- Development of an NT-ETA fusion protein targeting the neurotensin receptor.
- In vitro binding assays to confirm target recognition.
- Cytotoxicity assays using relevant tumor cell lines.
Main Results:
- Recombinant proteins demonstrated specific binding to their intended targets.
- NT-ETA fusion protein exhibited significant in vitro cytotoxicity against neurotensin receptor-positive tumor cells.
- scFv-ETA constructs targeting Le(a) and episialin did not show significant in vitro tumor toxicity.
- Specific cell binding alone was insufficient for potent tumor cell killing.
Conclusions:
- Careful selection of antigenic targets is crucial for developing effective tumor toxins.
- Seven transmembrane spanning receptors, like the neurotensin receptor, are viable targets for potent anti-tumor agents.
- Neurotensin receptor-targeted fusion proteins represent a promising new therapeutic strategy for specific cancers.